^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zamaporvint (RXC004)

    i
    Associations
    News

    Trials

    Company:
    Redx
    Drug class:
    PORCN inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (PORCUPINE) (NCT04907539)
    Phase 2
    Redx Pharma Plc
    Completed
    Last update posted :
    05/03/2024
    Initiation :
    11/08/2021
    Primary completion :
    04/02/2024
    Completion :
    04/02/2024
    RNF43 • RSPO2
    |
    Opdivo (nivolumab) • Prolia (denosumab) • zamaporvint (RXC004)
    A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) (NCT04907851)
    Phase 2
    Redx Pharma Plc
    Completed
    Last update posted :
    03/08/2024
    Initiation :
    12/10/2021
    Primary completion :
    11/30/2023
    Completion :
    11/30/2023
    RNF43
    |
    RNF43 mutation
    |
    Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)